<VariationArchive VariationID="627264" VariationName="NM_000130.5(F5):c.1830_1831dup (p.His611fs)" VariationType="Duplication" Accession="VCV000627264" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-07-15" DateCreated="2019-09-29" MostRecentSubmission="2023-10-07">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="615283" VariationID="627264">
      <GeneList>
        <Gene Symbol="F5" FullName="coagulation factor V" GeneID="2153" HGNC_ID="HGNC:3542" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q24.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="169511951" stop="169586481" display_start="169511951" display_stop="169586481" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="169481191" stop="169555768" display_start="169481191" display_stop="169555768" Strand="-" />
          </Location>
          <OMIM>612309</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000130.5(F5):c.1830_1831dup (p.His611fs)</Name>
      <CanonicalSPDI>NC_000001.11:169544439:GC:GCGC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>1q24.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="169544439" stop="169544440" display_start="169544439" display_stop="169544440" variantLength="2" positionVCF="169544439" referenceAlleleVCF="T" alternateAlleleVCF="TGC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="169513677" stop="169513678" display_start="169513677" display_stop="169513678" variantLength="2" positionVCF="169513677" referenceAlleleVCF="T" alternateAlleleVCF="TGC" />
      </Location>
      <ProteinChange>H611fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.169513678_169513679dup" Assembly="GRCh37">
            <Expression>NC_000001.10:g.169513678_169513679dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.169544440_169544441dup" Assembly="GRCh38">
            <Expression>NC_000001.11:g.169544440_169544441dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011806.1" sequenceAccession="NG_011806" sequenceVersion="1" change="g.47091_47092dup">
            <Expression>NG_011806.1:g.47091_47092dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000130.5" sequenceAccession="NM_000130" sequenceVersion="5" change="c.1830_1831dup" MANESelect="true">
            <Expression>NM_000130.5:c.1830_1831dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000121.2" sequenceAccession="NP_000121" sequenceVersion="2" change="p.His611fs">
            <Expression>NP_000121.2:p.His611fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_553" sequenceAccession="LRG_553">
            <Expression>LRG_553:g.47091_47092dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000130.4" sequenceAccession="NM_000130" sequenceVersion="4" change="c.1830_1831dupGC">
            <Expression>NM_000130.4:c.1830_1831dupGC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1571577365" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000130.5(F5):c.1830_1831dup (p.His611fs) AND Factor V deficiency" Accession="RCV000852059" Version="1">
        <ClassifiedConditionList TraitSetID="169">
          <ClassifiedCondition DB="MedGen" ID="C4317320">Factor V deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-02-01" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000130.5(F5):c.1830_1831dup (p.His611fs) AND Thrombophilia due to activated protein C resistance" Accession="RCV003333109" Version="1">
        <ClassifiedConditionList TraitSetID="168">
          <ClassifiedCondition DB="MedGen" ID="C1861171">Thrombophilia due to activated protein C resistance</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-12" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2019-09-29" MostRecentSubmission="2023-10-07">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">31064749</ID>
        </Citation>
        <DescriptionHistory Dated="2023-10-06">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="168" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4548" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Thrombophilia due to activated protein C resistance</ElementValue>
                <XRef ID="Thrombophilia+due+to+activated+protein+C+resistance/9393" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008560" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APC resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Resistance to Activated Protein C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PCCF DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="188055" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PROC COFACTOR DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="188055" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">THROMBOPHILIA DUE TO DEFICIENCY OF ACTIVATED PROTEIN C COFACTOR</ElementValue>
                <XRef Type="MIM" ID="188055" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">THROMBOPHILIA V</ElementValue>
                <XRef Type="MIM" ID="188055" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Activated protein C resistance</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">THPH2</ElementValue>
                <XRef Type="MIM" ID="188055" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">5FLE</ElementValue>
                <XRef ID="GTR000024913" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000559623" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332439" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502535" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521336" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531243" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320550" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509324" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000174331" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562501" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Factor V Leiden thrombophilia is characterized by a poor anticoagulant response to activated protein C (APC) and an increased risk for venous thromboembolism (VTE). Deep vein thrombosis (DVT) is the most common VTE, with the legs being the most common site. Thrombosis in unusual locations is less common. Evidence suggests that heterozygosity for the Leiden variant has at most a modest effect on risk for recurrent thrombosis after initial treatment of a first VTE. It is unlikely that factor V Leiden thrombophilia (i.e., heterozygosity or homozygosity for the Leiden variant) is a major factor contributing to pregnancy loss and other adverse pregnancy outcomes (preeclampsia, fetal growth restriction, and placental abruption). The clinical expression of factor V Leiden thrombophilia is influenced by the following: The number of Leiden variants (heterozygotes have a slightly increased risk for venous thrombosis; homozygotes have a much greater thrombotic risk). Coexisting genetic thrombophilic disorders, which have a supra-additive effect on overall thrombotic risk. Acquired thrombophilic disorders: antiphospholipid antibody (APLA) syndrome, paroxysmal nocturnal hemoglobinuria, myeloproliferative disorders, and increased levels of clotting factors. Circumstantial risk factors including but not limited to pregnancy, central venous catheters, travel, combined oral contraceptive (COC) use and other combined contraceptives, oral hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), obesity, leg injury, and advancing age.</Attribute>
                <XRef ID="NBK1368" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="274">gain of function</Attribute>
                <XRef ID="GTR000562560" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556386" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325434" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301542</ID>
                <ID Source="BookShelf">NBK1368</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2010">
                <ID Source="PubMed">20027064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng158</URL>
                <CitationText>UK NICE Guideline NG158, Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2023</CitationText>
              </Citation>
              <XRef ID="C1861171" DB="MedGen" />
              <XRef ID="MONDO:0008560" DB="MONDO" />
              <XRef Type="MIM" ID="188055" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="169" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1267" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Reduced coagulation factor V activity</ElementValue>
                <XRef ID="HP:0003225" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Factor V deficiency</ElementValue>
                <XRef ID="Factor+V+Deficiency/2709" DB="Genetic Alliance" />
                <XRef ID="HP:0003225" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0020586" DB="MONDO" />
                <XRef ID="4320005" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Factor V Leiden thrombophilia is characterized by a poor anticoagulant response to activated protein C (APC) and an increased risk for venous thromboembolism (VTE). Deep vein thrombosis (DVT) is the most common VTE, with the legs being the most common site. Thrombosis in unusual locations is less common. Evidence suggests that heterozygosity for the Leiden variant has at most a modest effect on risk for recurrent thrombosis after initial treatment of a first VTE. It is unlikely that factor V Leiden thrombophilia (i.e., heterozygosity or homozygosity for the Leiden variant) is a major factor contributing to pregnancy loss and other adverse pregnancy outcomes (preeclampsia, fetal growth restriction, and placental abruption). The clinical expression of factor V Leiden thrombophilia is influenced by the following: The number of Leiden variants (heterozygotes have a slightly increased risk for venous thrombosis; homozygotes have a much greater thrombotic risk). Coexisting genetic thrombophilic disorders, which have a supra-additive effect on overall thrombotic risk. Acquired thrombophilic disorders: antiphospholipid antibody (APLA) syndrome, paroxysmal nocturnal hemoglobinuria, myeloproliferative disorders, and increased levels of clotting factors. Circumstantial risk factors including but not limited to pregnancy, central venous catheters, travel, combined oral contraceptive (COC) use and other combined contraceptives, oral hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), obesity, leg injury, and advancing age.</Attribute>
                <XRef ID="NBK1368" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301542</ID>
                <ID Source="BookShelf">NBK1368</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2011">
                <ID Source="PubMed">21150787</ID>
              </Citation>
              <Citation Type="general" Abbrev="Retired, ACMG, 2001">
                <ID Source="pmc">3111091</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="ACMG, 2021">
                <ID Source="PubMed">33674767</ID>
              </Citation>
              <Citation Type="general" Abbrev="BSH, 2022">
                <ID Source="PubMed">35645034</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng158</URL>
                <CitationText>UK NICE Guideline NG158, Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, 2023</CitationText>
              </Citation>
              <XRef ID="326" DB="Orphanet" />
              <XRef ID="C4317320" DB="MedGen" />
              <XRef ID="MONDO:0020586" DB="MONDO" />
              <XRef Type="primary" ID="HP:0003225" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1769609" SubmissionDate="2019-03-28" DateLastUpdated="2019-09-29" DateCreated="2019-09-29">
        <ClinVarSubmissionID localKey="c.1830_1831dupGC_227400" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000899568" DateUpdated="2019-09-29" DateCreated="2019-09-29" Type="SCV" Version="1" SubmitterName="NIHR Bioresource Rare Diseases, University of Cambridge" OrgID="505998" OrganizationCategory="consortium" OrgAbbreviation="NIHR BR RD" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-02-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">31064749</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <TypePlatform>Targeted sequencing</TypePlatform>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">TGP0035</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="F5" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000130.4:c.1830_1831dupGC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="227400" Type="MIM" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">31064749</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31064749</ID>
        </Citation>
        <StudyName>ThromboGenomics</StudyName>
        <SubmissionNameList>
          <SubmissionName>ThromboGenomics</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7563010" SubmissionDate="2023-10-02" DateLastUpdated="2023-10-07" DateCreated="2023-10-07">
        <ClinVarSubmissionID localKey="49523|OMIM:188055" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004041516" DateUpdated="2023-10-07" DateCreated="2023-10-07" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000130.5:c.1830_1831dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="188055" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13858663</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1769609" TraitType="Disease" MappingType="XRef" MappingValue="227400" MappingRef="OMIM">
        <MedGen CUI="C0015499" Name="Congenital factor V deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7563010" TraitType="Disease" MappingType="XRef" MappingValue="188055" MappingRef="OMIM">
        <MedGen CUI="C1861171" Name="Thrombophilia due to activated protein C resistance" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

